Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ALL009
MIFTS: 53

Allergic Conjunctivitis

Categories: Eye diseases, Immune diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Allergic Conjunctivitis

About this section

MalaCards integrated aliases for Allergic Conjunctivitis:

Name: Allergic Conjunctivitis 12 15 17 74
Conjunctivitis, Allergic 45
Conjunctivitis Allergic 56

Classifications:

MalaCards categories:
Anatomical: Eye diseases Immune diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:11204
MeSH 45 D003233
NCIt 51 C34506
SNOMED-CT 69 20212001
UMLS 74 C0009766
Sources

Summaries for Allergic Conjunctivitis

About this section
Disease Ontology : 12 A chronic conjunctivitis that is an inflammation of the conjunctiva involing red, itchy, and watery eyes a resulting from an exposure to an allergen or an irritant.

MalaCards based summary : Allergic Conjunctivitis, also known as conjunctivitis, allergic, is related to giant papillary conjunctivitis and pollen allergy. An important gene associated with Allergic Conjunctivitis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Bepotastine and Ephedrine have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and skin, and related phenotypes are hematopoietic system and digestive/alimentary

Wikipedia : 77 Allergic conjunctivitis is inflammation of the conjunctiva (the membrane covering the white part of the... more...

Sources

Related Diseases for Allergic Conjunctivitis

About this section

Diseases related to Allergic Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 206)
# Related Disease Score Top Affiliating Genes
1 giant papillary conjunctivitis 31.6 CCL11 CXCL8 IL4 RNASE3
2 pollen allergy 31.2 FOXP3 ICAM1 IL13 IL5 RNASE3
3 allergic rhinitis 30.2 CCL11 CXCL8 HRH1 ICAM1 IFNG IL13
4 hypereosinophilic syndrome 29.9 CCL11 IL13 IL4 IL5 RNASE3
5 vernal keratoconjunctivitis 29.9 CCL11 ICAM1 IL13 IL4 IL5 RNASE3
6 uveitis 29.8 ICAM1 IFNG IL4
7 dermatitis 29.8 CCL11 IFNG IL13 IL4 IL5
8 chlamydia 29.7 CXCL8 IFNG IL4
9 scleritis 29.6 IFNG IL4 IL5
10 conjunctivitis 29.5 CCL11 CXCL8 HRH1 ICAM1 IFNG IL13
11 atopic keratoconjunctivitis 29.4 IFNG IL4 IL5 RNASE3
12 ige responsiveness, atopic 29.4 IFNG IL13 IL4 IL5 RNASE3
13 rhinitis 29.3 CCL11 CXCL8 HRH1 ICAM1 IL13 IL4
14 contact dermatitis 28.9 CXCL8 ICAM1 IFNG IL4 IL5
15 keratoconjunctivitis 28.8 CCL11 CXCL8 ICAM1 IFNG IL13 IL4
16 allergic hypersensitivity disease 28.6 CCL11 HRH1 IFNG IL13 IL4 IL5
17 allergic contact dermatitis 28.5 CXCL8 ICAM1 IFNG IL33 IL4 IL5
18 asthma 28.3 CCL11 CXCL8 HRH1 ICAM1 IFNG IL13
19 dermatitis, atopic 27.5 CCL11 CXCL8 FOXP3 HRH1 ICAM1 IFNG
20 loeffler endocarditis 10.4 IL5 RNASE3
21 cytokine deficiency 10.4 IL13 IL5
22 angioimmunoblastic lymphadenopathy with dysproteinemia 10.3 IL13 IL5
23 cow milk allergy 10.3 IL5 RNASE3
24 beta-lactam allergy 10.3 IL13 IL4
25 pemphigoid gestationis 10.3 CCL11 IL5
26 respiratory syncytial virus infectious disease 10.3 IL13 IL5
27 egg allergy 10.3 IL4 IL5
28 sulfamethoxazole allergy 10.3 IL4 IL5
29 trichinosis 10.3 IL4 IL5
30 chronic meningitis 10.3 CCL11 IL5
31 gaucher disease, type ii 10.3 IL4 IL5
32 non-suppurative otitis media 10.3 IL4 IL5
33 diversion colitis 10.3 ICAM1 IL4
34 ascaris lumbricoides infection 10.3 IL13 IL5
35 filarial elephantiasis 10.3 IL4 IL5
36 blepharoconjunctivitis 10.3 CCL11 IL4 RNASE3
37 actinic prurigo 10.2 ICAM1 IL13
38 tungiasis 10.2 CXCL8 IL4
39 cough variant asthma 10.2 IL4 IL5 RNASE3
40 intrinsic asthma 10.2 IL4 IL5 RNASE3
41 paragonimiasis 10.2 IL13 IL5 RNASE3
42 milk allergy 10.2 IL4 IL5 RNASE3
43 intestinal schistosomiasis 10.2 IL13 IL4 IL5
44 chronic tic disorder 10.2 IL13 IL4 IL5
45 eosinophilic gastroenteritis 10.2 CCL11 IL5 RNASE3
46 vulvovaginitis 10.2 CCL11 CXCL8
47 bagassosis 10.2 CXCL8 IL5
48 scabies 10.2 CCL11 CXCL8
49 enterobiasis 10.2 IL13 IL4 IL5
50 opisthorchiasis 10.2 CXCL8 IL4

Graphical network of the top 20 diseases related to Allergic Conjunctivitis:



Diseases related to Allergic Conjunctivitis
Sources

Symptoms & Phenotypes for Allergic Conjunctivitis

About this section

MGI Mouse Phenotypes related to Allergic Conjunctivitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 CCL11 FOXP3 HRH1 ICAM1 IFNG IL13
2 digestive/alimentary MP:0005381 9.98 FOXP3 ICAM1 IFNG IL13 IL33 IL4
3 homeostasis/metabolism MP:0005376 9.97 FOXP3 HRH1 ICAM1 IFNG IL13 IL33
4 immune system MP:0005387 9.96 CCL11 FOXP3 HRH1 ICAM1 IFNG IL13
5 endocrine/exocrine gland MP:0005379 9.95 FOXP3 ICAM1 IFNG IL13 IL33 IL4
6 integument MP:0010771 9.63 FOXP3 ICAM1 IFNG IL13 IL33 IL4
7 reproductive system MP:0005389 9.5 FOXP3 IFNG IL13 IL33 IL4 IL5
8 respiratory system MP:0005388 9.23 CCL11 FOXP3 IFNG IL13 IL33 IL4
Sources

Drugs & Therapeutics for Allergic Conjunctivitis

About this section

Drugs for Allergic Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bepotastine Approved Phase 4,Phase 3,Phase 2 190786-44-8, 125602-71-3 2350
2
Ephedrine Approved Phase 4,Phase 3,Phase 2 299-42-3 9294
3
Pheniramine Approved Phase 4 86-21-5 4761
4
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-45-6 774
5
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2 90-82-4 7028
6
Alcaftadine Approved Phase 4,Phase 3 147084-10-4 19371515
7
Naphazoline Approved, Investigational Phase 4,Phase 3 835-31-4 4436
8
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2 302-25-0
9
Loteprednol Approved, Experimental Phase 4,Phase 3,Phase 2 82034-46-6, 129260-79-3 9865442 444025
10
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
11
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2 2921-57-5
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
13
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3 104987-11-3 6473866 445643 439492
14
Ketotifen Approved Phase 4,Phase 3,Phase 1,Phase 2 34580-14-8, 34580-13-7 3827
15
Epinastine Approved, Investigational Phase 4,Phase 3 80012-43-7 3241
16
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 1177-87-3
18
Fluticasone Approved, Experimental Phase 4,Phase 2 90566-53-3 62924
19
Dipivefrin Approved Phase 4 52365-63-6 3105
20
Desloratadine Approved, Investigational Phase 4,Phase 3 100643-71-8 124087
21
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
22
Montelukast Approved Phase 4 158966-92-8 5281040
23
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
24
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
25
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 17753757 6447131
26
Calcium Approved, Nutraceutical Phase 4,Phase 2 7440-70-2 271
27
Glutamic Acid Approved, Nutraceutical Phase 4 56-86-0 33032
28
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
29
Prednisolone hemisuccinate Experimental Phase 4,Phase 2 2920-86-7
30
Tranilast Investigational Phase 4 53902-12-8 93543
31 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Adrenergic Agents Phase 4,Phase 3,Phase 2
36 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2
37 Histamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Adrenergic Agonists Phase 4,Phase 3,Phase 2
39 Nasal Decongestants Phase 4,Phase 3,Phase 2
40 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Histamine H1 Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Antipruritics Phase 4,Phase 3,Phase 1,Phase 2
43 Respiratory System Agents Phase 4,Phase 3,Phase 2
44 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2
45
Histamine Phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-74-1 65513
46 Hormones Phase 4,Phase 3,Phase 2
47 Hormone Antagonists Phase 4,Phase 3,Phase 2
48 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
49 glucocorticoids Phase 4,Phase 3,Phase 2
50 Methylprednisolone Acetate Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 229)
# Name Status NCT ID Phase Drugs
1 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4 Bepotastine
2 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
3 The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Unknown status NCT01346371 Phase 4 Bepreve (bepotastine ophthalmic solution) 1.5%
4 Ocular Allergy Treatment Practical Impact Trial Unknown status NCT01808768 Phase 4 Alcaftadine
5 A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% Unknown status NCT01437982 Phase 4 Loteprednol Etabonate;Prednisolone Acetate 1% Oph Susp
6 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
7 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
8 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
9 Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
10 A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
11 Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis Completed NCT01119287 Phase 4 Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
12 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
13 Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
14 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
15 A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis Completed NCT00655109 Phase 4 Olopatadine;Fluticasone;Saline;Artificial tears
16 Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication
17 Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis Completed NCT00534794 Phase 4 Elestat;Pataday
18 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
19 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4 Olopatadine hydrochloride ophthalmic solution 0.1%
20 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT00689078 Phase 4 Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Placebo
21 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
22 Assessment of Alcon's Ocular Image Quantification System Completed NCT01282138 Phase 4 Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
23 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4 Olopatadine (generic name)
24 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
25 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
26 A Study to Evaluate the Efficacy of Lastacaft® Compared to Patadayâ„¢ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
27 Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
28 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4 Lastacaft ®;Tears Naturale ®
29 Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
30 An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo Completed NCT01439815 Phase 4 Fluticasone Propionate Nasal Spray;Saline Nasal Spray
31 The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing Completed NCT01128556 Phase 4 Bepreve;Refresh Tears
32 A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209) Completed NCT00311844 Phase 4 desloratadine
33 Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
34 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4 montelukast
35 A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis Completed NCT03464435 Phase 4 Tacrolimus
36 Tolerability of Grazax in Patients With Hayfever in Real Life Settings Completed NCT01433510 Phase 4 Grazax
37 Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Completed NCT00357019 Phase 4 N-acetyl-aspartyl-glutamate (NAAXIA Sine)
38 Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX® Completed NCT02437786 Phase 4 GRAZAX
39 Efficacy of Co-administration of Bilastine and Montelukast in Patients With SARC and Asthma Completed NCT02761252 Phase 4 Bilastine 20mg;Montelukast 10mg;Placebo Bilastine 20mg;Placebo Montelukast 10mg
40 The Impact of Grass SLIT Treatment on Birch Pollen Induced Allergic Rhinitis - a Pilot Evaluation Completed NCT02394600 Phase 4 Grastek®;Placebo
41 PURETHAL Birch RUSH Study Completed NCT01918956 Phase 4
42 PURETHAL Grasses Rush Study Completed NCT01059266 Phase 4 PURETHAL Grasses, 20.000 AUM/ml
43 Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis Recruiting NCT03186755 Phase 4 Hyaluronic acid 0.05% & Ectoine 2.0%;Olopatadine hydrochloride ophthalmic solution 0.1%
44 Manuka Eye Droops for Treatment of Allergy Not yet recruiting NCT03862053 Phase 4 Manuka honey
45 Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan Terminated NCT00276445 Phase 4 beta-1,3-glucan
46 Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification Terminated NCT00124709 Phase 4 Pimecrolimus;Corticosteroid
47 Comparison of CL Wear Between Two Allergy Drops Withdrawn NCT00489398 Phase 4 epinastine HCL and olopatadine HCL
48 A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts Unknown status NCT01012752 Phase 3
49 Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008 Unknown status NCT00298337 Phase 2, Phase 3 Mixture of probiotic bacteria and prebiotic oligosaccharide
50 A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis Unknown status NCT00812799 Phase 3 Oralgen

Search NIH Clinical Center for Allergic Conjunctivitis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: conjunctivitis, allergic

Sources

Genetic Tests for Allergic Conjunctivitis

About this section
Sources

Anatomical Context for Allergic Conjunctivitis

About this section

MalaCards organs/tissues related to Allergic Conjunctivitis:

42
Eye, Testes, Skin, T Cells, Lung, Bone, Lymph Node
Sources

Publications for Allergic Conjunctivitis

About this section

Articles related to Allergic Conjunctivitis:

(show top 50) (show all 642)
# Title Authors Year
1
A Murine Model of Acute Allergic Conjunctivitis Induced by Continuous Exposure to Particulate Matter 2.5. ( 31099828 )
2019
2
Local allergic conjunctivitis: a phenotype of allergic conjunctivitis. ( 31093805 )
2019
3
Corrigendum to "Allergic Conjunctivitis-induced Retinal Inflammation Promotes Myopia Progression" [EBioMedicine 28 (2018) 274-286]. ( 30885727 )
2019
4
Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects. ( 30858690 )
2019
5
Bicanalicular Silicone Intubation for the Management of Punctal Stenosis and Obstruction in Patients With Allergic Conjunctivitis. ( 30844917 )
2019
6
Low Expression of IL-10 in Circulating Bregs and Inverted IL-10/TNF-α Ratio in Tears of Patients with Perennial Allergic Conjunctivitis: A Preliminary Study. ( 30818819 )
2019
7
Diagnosing and managing allergic conjunctivitis in childhood: the allergist's perspective. ( 30742722 )
2019
8
Dietary ω-3 fatty acids alter the lipid mediator profile and alleviate allergic conjunctivitis without modulating Th2 immune responses. ( 30383446 )
2019
9
Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model. ( 30587908 )
2018
10
The Prevalence of Allergic Rhinitis, Allergic Conjunctivitis, Atopic Dermatitis and Asthma among Adults of Tehran. ( 30581793 )
2018
11
IL-27 signaling deficiency develops Th17-enhanced Th2-dominant inflammation in murine allergic conjunctivitis model. ( 30515838 )
2018
12
Periostin deletion suppresses late-phase response in mouse experimental allergic conjunctivitis. ( 30420208 )
2018
13
Efficacy and Tolerability of Ketotifen in the Treatment Of Seasonal Allergic Conjunctivitis: Comparison between Ketotifen 0.025% and 0.05% Eye Drops. ( 30303746 )
2018
14
Oral Immunotherapy for Allergic Conjunctivitis Using Transgenic Rice Expressing Hypoallergenic Antigens. ( 30252684 )
2018
15
Investigation of possible risk factors in the development of seasonal allergic conjunctivitis. ( 30225226 )
2018
16
Neuropathic Pain and Itch Mechanisms Underlying Allergic Conjunctivitis. ( 30222114 )
2018
17
Mini-monoka stenting for patients with perennial allergic conjunctivitis. ( 30204032 )
2018
18
Allergy and Asthma: Allergic Rhinitis and Allergic Conjunctivitis. ( 30152668 )
2018
19
DS-70, a novel and potent α4 integrin antagonist, is an effective treatment for experimental allergic conjunctivitis in guinea pigs. ( 30051467 )
2018
20
Sublingual immunotherapy for pediatric allergic conjunctivitis: a meta-analysis of randomized controlled trials. ( 29782067 )
2018
21
Topical Olopatadine Hydrochloride versus Ketotifen Fumarate for Allergic Conjunctivitis. ( 29719638 )
2018
22
Effect of Pycnogenol® on an experimental rat model of allergic conjunctivitis. ( 29675725 )
2018
23
Variation in the TEK gene is not associated with asthma but with allergic conjunctivitis. ( 29667338 )
2018
24
Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis. ( 29615844 )
2018
25
Allergic conjunctivitis: current concepts on pathogenesis and management. ( 29552874 )
2018
26
Alcaftadine 0.25% versus Olopatadine 0.1% in Preventing Cedar Pollen Allergic Conjunctivitis in Japan: A Randomized Study. ( 29543548 )
2018
27
Rapamycin attenuates Th2-driven experimental allergic conjunctivitis. ( 29432811 )
2018
28
Allergic Conjunctivitis-induced Retinal Inflammation Promotes Myopia Progression. ( 29398596 )
2018
29
A Biodegradable, Sustained-Released, Tacrolimus Microfilm Drug Delivery System for the Management of Allergic Conjunctivitis in a Mouse Model. ( 29392313 )
2018
30
Tear osteopontin level and its relationship with local Th1/Th2/Th17/Treg cytokines in children with allergic conjunctivitis. ( 29279263 )
2018
31
Clinical implications of mast cell involvement in allergic conjunctivitis. ( 29105783 )
2018
32
Evaluation of allergic sensitization in Lebanese patients with allergic conjunctivitis. ( 28831678 )
2018
33
Nitrite, neopterin levels and tryptophan degradation in allergic conjunctivitis. ( 28779270 )
2018
34
Efficacy of oral immunotherapy with a rice-based edible vaccine containing hypoallergenic Japanese cedar pollen allergens for treatment of established allergic conjunctivitis in mice. ( 28676431 )
2018
35
Increased red cell distribution width levels in children with seasonal allergic conjunctivitis. ( 28523524 )
2018
36
TRPV1 Antagonist Suppresses Allergic Conjunctivitis in a Murine Model. ( 27726468 )
2018
37
Allergic conjunctivitis. ( 29849438 )
2017
38
Validity of Specific Immunoglobulin E Assay in Tear Film for Detection of Allergens Inducing Different Types of Allergic Conjunctivitis. ( 29528586 )
2017
39
Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment. ( 29026285 )
2017
40
Model for Studying Anti- Allergic Drugs for Allergic Conjunctivitis in Animals. ( 28848937 )
2017
41
MiR-146a overexpression effectively improves experimental allergic conjunctivitis through regulating CD4+CD25-T cells. ( 28810531 )
2017
42
Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis. ( 28656804 )
2017
43
Novel oleyl amine-modified polymannuronic acid micelle loading tacrolimus for therapy of allergic conjunctivitis. ( 28655660 )
2017
44
Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis. ( 28652694 )
2017
45
Risk of allergic conjunctivitis in patients with type 1 diabetes mellitus: a population-based retrospective cohort study. ( 28630085 )
2017
46
Effect of Mandarin Orange Yogurt on Allergic Conjunctivitis Induced by Conjunctival Allergen Challenge. ( 28593244 )
2017
47
Allergic conjunctivitis in Asia. ( 28487836 )
2017
48
Allergic Conjunctivitis in Patients with Respiratory Allergic Symptoms; a Retrospective Study in Greece. ( 28428968 )
2017
49
Self-Reported Allergic Rhinitis and/or Allergic Conjunctivitis Associate with IL13 rs20541 Polymorphism in Finnish Adult Asthma Patients. ( 28273659 )
2017
50
An inhibitor peptide of toll-like receptor 2 shows therapeutic potential for allergic conjunctivitis. ( 28246054 )
2017
Sources

Variations for Allergic Conjunctivitis

About this section
Sources

Expression for Allergic Conjunctivitis

About this section
Search GEO for disease gene expression data for Allergic Conjunctivitis.
Sources

Pathways for Allergic Conjunctivitis

About this section

Pathways related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 13.88 CCL11 CXCL8 ICAM1 IFNG IL13 IL33
2
PEDF Induced Signaling 65
Show member pathways
 13.55 CCL11 CXCL8 IFNG IL13 IL33 IL4
3
TGF-Beta Pathway 65
Show member pathways
 13.42 CCL11 CXCL8 ICAM1 IFNG IL13 IL4
4
Akt Signaling 65
Show member pathways
 13.29 CCL11 CXCL8 IL13 IL4 IL5 TLR3
5
Cytokine Signaling in Immune system 67
Show member pathways
 13.26 CCL11 CXCL8 ICAM1 IFNG IL13 IL33
6
Pathways in cancer 38
12.74 CXCL8 IFNG IL13 IL4 IL5
7
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways 67
Show member pathways
 12.65 CXCL8 IFNG IL33 TLR3
8
Th17 cell differentiation 38
Show member pathways
 12.52 FOXP3 IFNG IL13 IL4 IL5
9
NF-kappaB Signaling 4
12.47 FOXP3 IFNG IL4 TLR3
10
Allograft rejection 38 1
Show member pathways
 12.35 CCL11 CXCL8 FOXP3 ICAM1 IFNG IL13
11
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.31 IFNG IL13 IL4 IL5
12
IL-17 Family Signaling Pathways 66
Show member pathways
 12.27 CCL11 CXCL8 IFNG IL13 IL4 IL5
13
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.18 CXCL8 IFNG IL13 IL4 IL5
14
Bacterial infections in CF airways 23
Show member pathways
 12.12 CCL11 CXCL8 IFNG IL4
15
G-protein signaling Regulation of p38 and JNK signaling mediated by G-proteins 23
Show member pathways
 12.1 CCL11 CXCL8 ICAM1 TLR3
16
Necroptosis 38
Show member pathways
 12.1 IFNG IL33 TLR3
17
Interleukin-4 and 13 signaling 67
11.97 CCL11 CXCL8 ICAM1 IL13 IL4
18
Microglia Activation During Neuroinflammation: Overview 66
Show member pathways
 11.95 IFNG IL13 IL4
19
Spinal Cord Injury 1
11.95 CXCL8 ICAM1 IFNG IL4
20
MAPK Pathway 73
Show member pathways
 11.94 IL13 IL5 TLR3
21
Immune response IFN gamma signaling pathway 23
Show member pathways
 11.93 CCL11 CXCL8 ICAM1 IFNG IL13 IL4
22
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.91 IFNG IL4 IL5
23
Cytokine production by Th17 cells in CF (Mouse model) 23
Show member pathways
 11.8 CXCL8 FOXP3 ICAM1
24
Rheumatoid arthritis 38
11.79 CXCL8 ICAM1 IFNG
25
Innate Lymphoid Cell Differentiation Pathways 66
11.73 IFNG IL13 IL33 IL4 IL5
26
Microglia Activation During Neuroinflammation: Microglia Polarization 66
11.71 CCL11 IFNG IL13 IL4
27
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.68 CXCL8 FOXP3 IFNG IL4 IL5
28
IL4-mediated signaling events 1
11.61 CCL11 IL4 IL5
29
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.6 CXCL8 ICAM1 IFNG
30
Glucocorticoid receptor regulatory network 1
11.55 CXCL8 ICAM1 IFNG IL13 IL4 IL5
31
Interleukin-10 signaling 67
11.52 CXCL8 ICAM1 IL13 IL4
32
Lung fibrosis 1
11.52 CCL11 CXCL8 IL13 IL4 IL5
33
Malaria 38
11.48 CXCL8 ICAM1 IFNG
34
Immune response_Role of integrins in NK cells cytotoxicity 23
11.43 CXCL8 ICAM1 IFNG
35
Inflammatory Response Pathway 1
11.29 IFNG IL4 IL5
36
Cytokines and Inflammatory Response 1
11.26 IFNG IL13 IL4 IL5
37
OX40 Pathway 65
11.19 IFNG IL13 IL4 IL5
38
G-protein signaling_RhoB regulation pathway 23
11.16 CCL11 CXCL8 IL13 IL4 IL5
39
Development and heterogeneity of the ILC family 1
11.16 IFNG IL13 IL33 IL4 IL5
40
IL12 signaling mediated by STAT4 1
11.13 IFNG IL13
41
IL1 and megakaryocytes in obesity 1
11.08 ICAM1 IFNG
42
G-protein signaling_Rap2B regulation pathway 23
10.94 CCL11 CXCL8 IL13 IL4 IL5
43
Th2 Differentiation Pathway 66
10.83 CCL11 FOXP3 IFNG IL13 IL33 IL4
Sources

GO Terms for Allergic Conjunctivitis

About this section

Cellular components related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 CCL11 CXCL8 IFNG IL13 IL33 IL4
2 extracellular space GO:0005615 9.32 CCL11 CXCL8 ICAM1 IFNG IL13 IL33

Biological processes related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 defense response to virus GO:0051607 9.81 IFNG IL33 TLR3
2 immune response GO:0006955 9.8 CCL11 CXCL8 IFNG IL13 IL4 IL5
3 positive regulation of angiogenesis GO:0045766 9.77 CCL11 CXCL8 TLR3
4 cellular response to tumor necrosis factor GO:0071356 9.75 CCL11 CXCL8 ICAM1
5 positive regulation of gene expression GO:0010628 9.73 FOXP3 IFNG IL13 IL33 IL4 TLR3
6 cellular response to interferon-gamma GO:0071346 9.71 CCL11 ICAM1 TLR3
7 cellular response to interleukin-1 GO:0071347 9.69 CCL11 CXCL8 ICAM1
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.67 IFNG IL13 IL4
9 response to virus GO:0009615 9.67 CCL11 FOXP3 IFNG TLR3
10 extrinsic apoptotic signaling pathway GO:0097191 9.65 IFNG IL33 TLR3
11 positive regulation of vasoconstriction GO:0045907 9.64 HRH1 ICAM1
12 negative regulation of interferon-gamma production GO:0032689 9.63 FOXP3 IL33
13 inflammatory response GO:0006954 9.63 CCL11 CXCL8 HRH1 IL13 IL5 TLR3
14 positive regulation of interleukin-12 production GO:0032735 9.62 IFNG TLR3
15 negative regulation of osteoclast differentiation GO:0045671 9.62 IL4 TLR3
16 eosinophil chemotaxis GO:0048245 9.61 CCL11 HRH1
17 positive regulation of interleukin-4 production GO:0032753 9.61 FOXP3 IL33
18 positive regulation of B cell proliferation GO:0030890 9.61 IL13 IL4 IL5
19 microglial cell activation GO:0001774 9.59 IL13 TLR3
20 positive regulation of macrophage activation GO:0043032 9.58 IL13 IL33
21 negative regulation of endothelial cell apoptotic process GO:2000352 9.58 ICAM1 IL13 IL4
22 regulation of regulatory T cell differentiation GO:0045589 9.57 FOXP3 IFNG
23 negative regulation of interleukin-17 production GO:0032700 9.56 FOXP3 IFNG
24 positive regulation of immunoglobulin secretion GO:0051024 9.55 IL33 IL5
25 positive regulation of interleukin-13 production GO:0032736 9.52 IL33 IL4
26 negative regulation of complement-dependent cytotoxicity GO:1903660 9.46 IL13 IL4
27 cytokine-mediated signaling pathway GO:0019221 9.43 CCL11 CXCL8 ICAM1 IL13 IL4 IL5
28 regulation of signaling receptor activity GO:0010469 9.17 CCL11 CXCL8 IFNG IL13 IL33 IL4

Molecular functions related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 CCL11 CXCL8 IFNG IL13 IL33 IL4
2 cytokine receptor binding GO:0005126 8.96 IL13 IL4
Sources

Sources for Allergic Conjunctivitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....